We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+50.27%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$66.5M
Cap. Flow
-$114M
Cap. Flow %
-45.59%
Top 10 Hldgs %
68.57%
Holding
50
New
9
Increased
9
Reduced
16
Closed
16

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$5.33M
2
PRTA icon
Prothena Corp
PRTA
+$3.98M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.57M
4
PRVA icon
Privia Health
PRVA
+$2.96M
5
KIDS icon
OrthoPediatrics
KIDS
+$2.75M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$31.6M
2
PCRX icon
Pacira BioSciences
PCRX
+$27.9M
3
KURA icon
Kura Oncology
KURA
+$9.66M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.5M
5
INSP icon
Inspire Medical Systems
INSP
+$7.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Industrials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$33.6M 13.5%
827,294
+97,087
+13% +$3.57M
MGTX icon
2
MeiraGTx Holdings
MGTX
$1.09B
$28.4M 11.42%
4,050,714
-28,090
-0.7% -$139K
STTK icon
3
Shattuck Labs
STTK
$710M
$19.8M 7.97%
2,782,797
+659,797
+31% +$1.8M
MDT icon
4
Medtronic
MDT
$107B
$18.1M 7.28%
220,000
+70,000
+47% +$5.33M
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.25B
$14.5M 5.83%
1,578,263
-1,001,539
-39% -$7.24M
KURA icon
6
Kura Oncology
KURA
$922M
$13.7M 5.48%
950,000
-982,456
-51% -$9.66M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.37B
$13.4M 5.37%
2,232,242
-175,893
-7% -$1.02M
ADCT icon
8
ADC Therapeutics
ADCT
$146M
$10.7M 4.31%
6,471,800
+1,069,759
+20% +$987K
ABCL icon
9
AbCellera Biologics
ABCL
$1.62B
$9.71M 3.9%
1,700,000
-746,000
-30% -$3.46M
QDEL icon
10
QuidelOrtho
QDEL
$1.09B
$8.76M 3.52%
118,920
+33,920
+40% +$2.29M
PCRX icon
11
Pacira BioSciences
PCRX
$1.02B
$8.72M 3.5%
258,424
-951,953
-79% -$27.9M
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.89B
$8.66M 3.48%
293,301
-60,207
-17% -$1.82M
PRTA icon
13
Prothena Corp
PRTA
$458M
$8.34M 3.35%
229,539
+103,337
+82% +$3.98M
OPCH icon
14
Option Care Health
OPCH
$3.4B
$5.01M 2.01%
148,800
-71,200
-32% -$2.19M
LKFT
15
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$4.88M 1.96%
+120,000
New +$4.42M
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.7B
$4.73M 1.9%
35,900
-44,100
-55% -$5.08M
UHS icon
17
Universal Health Services
UHS
$9.43B
$4.28M 1.72%
28,090
-12,800
-31% -$1.72M
LENZ
18
LENZ Therapeutics
LENZ
$172M
$3.54M 1.42%
193,134
+2,016
+1% +$33.3K
KZR
19
DELISTED
Kezar Life Sciences
KZR
$3.19M 1.28%
336,533
-140,547
-29% -$1.24M
NUVB icon
20
Nuvation Bio
NUVB
$2.24B
$3.1M 1.24%
2,050,000
+1,000,000
+95% +$1.29M
KIDS icon
21
OrthoPediatrics
KIDS
$485M
$3.09M 1.24%
+95,000
New +$2.75M
PRVA icon
22
Privia Health
PRVA
$3.21B
$3.04M 1.22%
+132,158
New +$2.96M
DXCM icon
23
DexCom
DXCM
$27.6B
$2.85M 1.15%
23,000
-39,421
-63% -$4.03M
MURA
24
DELISTED
Mural Oncology
MURA
$2.48M 0.99%
+418,505
New +$1.68M
PRTA icon
25
CALL
Prothena Corp
PRTA
$458M
$1.94M 0.78%
+53,500
New +$2.06M
1
2

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2023 Portfolio in Review

As of Q4 2023, Prosight Management held 50 positions worth $249M, down 21% from $316M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Prosight Management withdrew a net $114M in Q4 2023, closing 16 positions and reducing 16 holdings. Its most notable exit was Humana, an estimated $31.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Prosight Management opened a new position in Privia Health worth $3.04M.

  • Prosight Management's largest Q4 2023 buy was Privia Health: 132,158 shares worth $3.04M.
  • Prosight Management added most to Medtronic in Q4 2023, an estimated $5.33M increase.
  • Prosight Management's biggest Q4 2023 reduction was Pacira BioSciences, cutting an estimated $27.9M.
  • Prosight Management fully exited Humana in Q4 2023, selling an estimated $31.6M.
  • Prosight Management's ten largest holdings make up 69% of its $249M portfolio in Q4 2023.
  • Prosight Management opened 9 new positions and closed 16 in Q4 2023.
  • Prosight Management's portfolio value fell 21% quarter-over-quarter to $249M.

Based on Prosight Management's 13F filing for Q4 2023, filed 14 Feb 2024.